The 25 most recent market catalysts affecting $VSTM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 18, 2026
Corporate Catalyst
Neutral
Impact 65
Verastem Oncology Announces Late-Breaking Oral Presentation of VS-7375 Lung Cancer Data
Verastem Oncology (VSTM) has been selected to give an oral presentation of updated clinical data from its Phase 1/2 TARGET-D-101 study of VS-7375 in KRAS G12D-mutated metastatic NS…
Nov 5, 2026
Corporate Catalyst
Neutral
Impact 92
Verastem Oncology Reports Third Quarter 2026 Financial Results
Verastem Oncology reported third-quarter 2026 financial results that were significantly below analyst consensus, with net product revenue of $24.0 million against estimates of $26.…
Oct 19, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Reiterates Buy on Verastem, Maintains $24 Price Target
BTIG analyst Jeet Mukherjee has reaffirmed a 'Buy' rating and a $24 price target for Verastem (VSTM). This action signals that the analyst's investment thesis for the company remai…
Oct 16, 2026
Corporate Catalyst
Bullish
Impact 60
Mizuho Maintains Outperform on Verastem, Raises Price Target to $14
Mizuho analyst Graig Suvannavejh maintained an 'Outperform' rating on Verastem (VSTM) and raised the price target from $13 to $14. This action indicates a continued positive sentim…
Oct 15, 2026
Corporate Catalyst
Bullish
Impact 75
Verastem shares are trading higher after multiple analysts raised their respective price targets on the stock.
The multiple analyst price target increases for Verastem (VSTM) are a significant positive catalyst. This indicates that professional investors and researchers believe the company'…
Oct 15, 2026
Corporate Catalyst
Bullish
Impact 55
Jefferies Maintains Buy on Verastem, Raises Price Target to $13
Jefferies analyst Faisal Khurshid maintained a 'Buy' rating on Verastem and raised the price target from $11 to $13. This action signals increased confidence from a prominent finan…
Oct 15, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Verastem, Raises Price Target to $19
RBC Capital's analyst Leonid Timashev has maintained an 'Outperform' rating for Verastem and raised the price target from $14 to $19. This analyst action signals increased confiden…
Oct 15, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Verastem, Raises Price Target to $24
BTIG analyst Jeet Mukherjee maintained a 'Buy' rating on Verastem (VSTM) and raised the price target from $18 to $24. This action signals increased analyst confidence in Verastem's…
Oct 14, 2026
Corporate Catalyst
Bullish
Impact 85
Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers
Verastem Oncology's 8-K filing is a significant corporate catalyst. The positive early clinical results for VS-7375, particularly the 41% objective response rate in metastatic panc…
Oct 14, 2026
Corporate Catalyst
Bullish
Impact 92
Verastem Oncology shares are trading higher after strong early Phase 1/2 data for VS-7375 in KRAS G12D-mutated cancers, alongside a CEO transition and the pricing of a $250 million public offering to support development efforts.
This headline represents a major catalyst for Verastem Oncology. The strong early Phase 1/2 data for VS-7375 in KRAS G12D-mutated cancers is a significant de-risking event, as KRAS…
Oct 14, 2026
Corporate Catalyst
Neutral
Impact 75
Verastem Oncology Priced Underwritten Offering Of 30.94M Common Shares At $8.00 Per Share For $247.5M In Gross Proceeds
This underwritten offering by Verastem Oncology is a significant corporate catalyst. The issuance of 30.94 million new shares at $8.00 per share will dilute existing shareholders, …
Oct 14, 2026
Corporate Catalyst
Neutral
Impact 75
Verastem Oncology Appoints Michael P. Bailey As President And CEO, Effective January 1, 2027
Verastem Oncology is undergoing a planned CEO transition, with Michael P. Bailey taking over from Daniel Paterson on January 1, 2027. This matters because Paterson has been a pivot…
Oct 14, 2026
Corporate Catalyst
Bullish
Impact 85
Verastem Oncology Announces Initial Data In First Multi-Tumor Update From Ongoing TARGET-D 101 Phase 1/2 Clinical Trial Evaluating VS-7375; Data Demonstrate Robust Clinical Activity With Favorable Safety And Tolerability Profile Across Multiple Dose Levels And Tumor Types
Verastem Oncology released initial data from its Phase 1/2 trial for VS-7375, highlighting strong efficacy in pancreatic, colorectal, and non-small cell lung cancers, alongside a g…
Oct 5, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado has reiterated a 'Buy' rating on Verastem (VSTM) and maintained an $18 price target. This action signifies that the analyst's outloo…
Oct 2, 2026
Corporate Catalyst
Bullish
Impact 75
Verastem Oncology To Present Data From New Molecular Profiling, Tumor Biomarker Analysis Of Phase 2 RAMP 201 Clinical Trial Of Avutometinib Plus Defactinib In Patients With Recurrent LGSOC, At IGCS 2026
Verastem Oncology (VSTM) released new, positive data from its Phase 2 RAMP 201 clinical trial for avutometinib plus defactinib in recurrent low-grade serous ovarian cancer (LGSOC).…
Sep 24, 2026
Corporate Catalyst
Bullish
Impact 75
Verastem Oncology Announces Presentation Of Phase 2 Biomarker Analysis For Avutometinib Plus Defactinib In Low-Grade Serous Ovarian Cancer
The announcement of positive Phase 2 biomarker analysis for Verastem Oncology's drug combination (avutometinib plus defactinib) in low-grade serous ovarian cancer is a significant …
Sep 17, 2026
Corporate Catalyst
Neutral
Impact 65
Wolfe Research Initiates Coverage On Verastem with Outperform Rating
Wolfe Research has initiated coverage on Verastem (VSTM) with an 'Outperform' rating. This is a positive development for the company as new analyst coverage, especially with a favo…
Sep 11, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado has reiterated a 'Buy' rating and an $18 price target for Verastem. This action signals that the analyst's previous positive outlook…
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 75
Verastem Oncology To Host Investor Event On October 14 To Present Initial Efficacy And Updated Data For VS-7375 In Pancreatic, Lung, And Colorectal Cancers From Ongoing TARGET-D Clinical Development Program
Verastem Oncology is hosting an investor event to present new efficacy and updated safety data for VS-7375, a KRAS G12D inhibitor, in multiple cancer types. This is a crucial updat…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 55
Mizuho Maintains Outperform on Verastem, Lowers Price Target to $13
Mizuho analyst Graig Suvannavejh maintained an 'Outperform' rating on Verastem, indicating continued confidence in the company's long-term prospects. However, the simultaneous redu…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 55
Guggenheim Maintains Buy on Verastem, Lowers Price Target to $12
Guggenheim analyst Michael Schmidt maintained a 'Buy' rating on Verastem, signaling continued confidence in the company's fundamentals or pipeline. However, the simultaneous reduct…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 85
Verastem shares are trading higher after the company reported better-than-expected Q2 financial results.
This headline represents a significant corporate catalyst for Verastem. Better-than-expected financial results often lead to increased investor confidence, driving up share prices.…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 85
Verastem shares are trading higher after the company reported better-than-expected Q2 financial results.
This headline represents a significant corporate catalyst for Verastem, driving its shares higher due to better-than-expected Q2 financial results. The impact score is high because…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 92
Verastem Q2 Adj. EPS $(0.35) Beats $(0.43) Estimate, Sales $25.078M Beat $23.093M Estimate
Verastem (VSTM) announced Q2 adjusted EPS of $(0.35), significantly beating the analyst estimate of $(0.43), and sales of $25.078 million, surpassing the $23.093 million estimate. …
Jul 22, 2026
Corporate Catalyst
Neutral
Impact 65
Verastem Oncology Doses First Patient In Phase 2 Trial Of VS-7375 For KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer And Untreated Asymptomatic Untreated Brain Metastases
Verastem Oncology has initiated its Phase 2 trial for VS-7375, a drug targeting a specific mutation in advanced non-small cell lung cancer and brain metastases. This 'first patient…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.